Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrotech Corporation stock logo
ASTC
Astrotech
$5.68
+1.3%
$5.79
$5.34
$12.29
$9.59M0.2515,012 shs2,459 shs
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.65
$0.03
$2.09
$857K0.22537,509 shs53.64 million shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$11.17
+1.9%
$7.87
$3.91
$13.99
$757.25M1.67820,470 shs297,645 shs
Fluidigm Co. stock logo
FLDM
Fluidigm
$3.66
$2.67
$7.51
$283.76M1.14968,838 shs60,126 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$0.45
-1.2%
$0.43
$0.28
$3.60
$19.98M1.523.15 million shs318,712 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrotech Corporation stock logo
ASTC
Astrotech
-0.36%0.00%-2.61%-9.24%-34.04%
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00%0.00%0.00%-93.02%-96.48%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+10.15%+13.46%+22.73%+128.33%+24.97%
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00%0.00%0.00%0.00%0.00%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-0.20%-2.58%-18.07%+18.59%-83.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astrotech Corporation stock logo
ASTC
Astrotech
N/AN/AN/AN/AN/AN/AN/AN/A
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.8094 of 5 stars
3.53.00.00.03.71.70.0
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
4.1413 of 5 stars
3.34.00.04.51.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrotech Corporation stock logo
ASTC
Astrotech
0.00
N/AN/AN/A
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
4.00
Strong BuyN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$25.67131.75% Upside
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00
N/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.50
Moderate Buy$3.00563.72% Upside

Current Analyst Ratings Breakdown

Latest AXDX, EYPT, FLDM, HBIO, and ASTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$28.00
5/29/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/16/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/13/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$4.50 ➝ $3.00
5/8/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrotech Corporation stock logo
ASTC
Astrotech
$1.66M5.78N/AN/A$20.45 per share0.28
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$11.70M0.00N/AN/A($1.37) per share0.00
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$43.27M17.61N/AN/A$4.93 per share2.25
Fluidigm Co. stock logo
FLDM
Fluidigm
$130.58M0.00N/AN/A$1.24 per share0.00
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$94.14M0.21$0.10 per share4.54$1.45 per share0.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrotech Corporation stock logo
ASTC
Astrotech
-$11.67M-$8.42N/AN/A-1,536.99%-46.37%-42.51%9/17/2025 (Estimated)
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$61.62M-$2.34N/AN/AN/A-471.83%N/A-191.66%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.41N/AN/AN/A-261.91%-54.27%-41.75%8/6/2025 (Estimated)
Fluidigm Co. stock logo
FLDM
Fluidigm
-$59.24M-$0.78N/AN/AN/A-45.36%-40.15%-14.86%N/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$12.40M-$1.32N/AN/A-63.51%-4.96%-2.24%8/14/2025 (Estimated)

Latest AXDX, EYPT, FLDM, HBIO, and ASTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.67N/AN/AN/A$6.82 millionN/A
5/13/2025Q3 2025
Astrotech Corporation stock logo
ASTC
Astrotech
N/A-$2.18N/A-$2.18N/AN/A
5/7/2025Q1 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astrotech Corporation stock logo
ASTC
Astrotech
N/AN/AN/AN/AN/A
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrotech Corporation stock logo
ASTC
Astrotech
N/A
9.86
8.76
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/A
1.50
1.34
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
7.85
7.79
Fluidigm Co. stock logo
FLDM
Fluidigm
0.68
1.45
1.03
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/A
0.81
0.40

Institutional Ownership

CompanyInstitutional Ownership
Astrotech Corporation stock logo
ASTC
Astrotech
24.35%
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17.14%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Fluidigm Co. stock logo
FLDM
Fluidigm
76.59%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%

Insider Ownership

CompanyInsider Ownership
Astrotech Corporation stock logo
ASTC
Astrotech
14.90%
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
43.60%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
4.46%
Fluidigm Co. stock logo
FLDM
Fluidigm
2.90%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
9.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrotech Corporation stock logo
ASTC
Astrotech
101.69 million1.44 millionNot Optionable
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
22025.21 million14.13 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.81 million65.74 millionOptionable
Fluidigm Co. stock logo
FLDM
Fluidigm
61576.49 million74.27 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
49044.21 million40.01 millionOptionable

Recent News About These Companies

Trump admin comes for Harvard’s accreditation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astrotech stock logo

Astrotech NASDAQ:ASTC

$5.68 +0.08 (+1.34%)
As of 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. The company was incorporated in 1984 and is based in Austin, Texas.

Accelerate Diagnostics stock logo

Accelerate Diagnostics NASDAQ:AXDX

$0.04 +0.04 (+∞)
As of 05/14/2025
This is a fair market value price provided by Polygon.io. Learn more.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$11.16 +0.21 (+1.87%)
As of 03:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Fluidigm stock logo

Fluidigm NASDAQ:FLDM

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$0.45 -0.01 (-1.18%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.